JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Stock List・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Closed

SectorHealthcare

38.99 -0.1

Buy Sell

Overview

Share price change

24h

Current

Min

38.75

Max

39.11

Key metrics
By Trading Economics
Income	7.3M -123M
Sales	3.7M 3.9M
EPS	-1.29
Profit margin	-3,161.261
Employees	594
EBITDA	20M -122M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+109.53% upside

Dividends
By Dow Jones
Next Earnings	7 May 2026

Market Stats
By TradingEconomics
Market Cap	-445M 4B
Previous open	39.09
Previous close	38.99

News Sentiment

By Acuity

50%

116 / 347 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

30.39 / 33.46 Support & Resistance

Crinetics Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

5 May 2026, 23:43 UTC

Major News Events

New Zealand's Unemployment Rate Falls in 1Q

5 May 2026, 23:20 UTC

Hot Stocks

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 May 2026, 21:48 UTC

Earnings

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 May 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 May 2026, 00:00 UTC

Market Talk

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 May 2026, 23:39 UTC

Market Talk

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 May 2026, 22:26 UTC

Market Talk

AMD Data-Center Business Continues to Surge -- Market Talk

5 May 2026, 22:20 UTC

Market Talk

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 May 2026, 22:08 UTC

Earnings

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 May 2026, 22:07 UTC

Earnings

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 May 2026, 21:48 UTC

Earnings

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 May 2026, 21:48 UTC

Earnings

Pan American Silver 1Q Rev $1.2B >PAAS

5 May 2026, 21:42 UTC

Earnings

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 May 2026, 21:38 UTC

Earnings

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 May 2026, 21:30 UTC

Earnings

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 May 2026, 21:29 UTC

Earnings

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 May 2026, 21:26 UTC

Earnings

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 May 2026, 21:25 UTC

Earnings

Alcon Inc. 1Q EPS 39c >ALC.EB

5 May 2026, 21:25 UTC

Earnings

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 May 2026, 21:24 UTC

Earnings

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 May 2026, 21:18 UTC

Earnings

Mistras Backs 2026 Rev $730M-$750M >MG

5 May 2026, 21:17 UTC

Earnings

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 May 2026, 21:15 UTC

Earnings

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 May 2026, 21:12 UTC

Earnings

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 May 2026, 21:11 UTC

Earnings

SSR Mining 1Q Rev $581.8M >SSRM

5 May 2026, 21:10 UTC

Earnings

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 May 2026, 21:10 UTC

Earnings

SSR Mining 1Q EPS $1.16 >SSRM

5 May 2026, 21:08 UTC

Earnings

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 May 2026, 21:01 UTC

Earnings

Intact Financial 1Q EPS C$4.12 >IFC.T

5 May 2026, 21:01 UTC

Hot Stocks

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Peer Comparison

Price change

Crinetics Pharmaceuticals Inc Forecast

Price Target

By TipRanks

109.53% upside

12 Months Forecast

Average 86.43 USD 109.53%

High 97 USD

Low 67 USD

Based on 8 Wall Street analysts offering 12 month price targets forCrinetics Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Crinetics Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

30.39 / 33.46Support & Resistance

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

116 / 347 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.